medigraphic.com
ISSN 1561-2988 (Print)

2014, Number 1

<< Back Next >>

Rev Cubana Farm 2014; 48 (1)

Use of Yellow Card and of NOM220 Format for reporting of suspected adverse drug reactions

Carrillo-Alarcón LC, Ponce MHA, López LE, Velázquez AP, Ortiz MI

Language: Spanish
References: 36
Page: 96-107
PDF size: 196.35 Kb.


ABSTRACT

Introduction: the reporting of adverse drug reactions is a global obligation. Although many methods have been implemented, there are still problems at present.
Objective: to determine the frequency of suspected adverse reactions in patients and to compare the access to filling out the NOM220 formats of the Secretaría de Salud and the Yellow Card suggested by the World Health Organization.
Methods: a cross-sectional and observational study was made. Fifty physicians responsible for the diabetes clinics in the state of Hidalgo participated in the study. First, the physicians were trained to identify the suspected adverse drug reactions in their patients. A crossover design was created where 50 % of physicians used the NOM220 format and 50 % the Yellow Card. Three months later, they exchanged the formats and used them during the following three months. After this period, questionnaire was administered to determine the usefulness, clarity, filling out time and convenience of the formats. Descriptive statistics and bivariate analyses were applied to determine the factors associated with the suspected adverse drug reactions with SPSS software (version 17).
Results: a total of 46 suspected adverse reactions were registered in 46 patients using NOM220 format and 78 with the Yellow Card in 78 patients. All the suspected adverse reactions were type A. The physicians recommended the use of Yellow Card since they considered that it is practical, simple, readable, understandable, accessible and requires less time to fill it out (p ‹ 0.05).
Conclusions: the results allow selecting the Yellow Card as the most accessible choice for reporting suspected drug adverse reactions; additionally, they suggest that adjustments should be also made in the NOM220 format.


REFERENCES

  1. Sigala C, Nelle H, Halabe J. El resurgimiento de la talidomida. Rev Fac Med UNAM. 2001;44(5):212-5.

  2. Rodríguez-Betancourt JL, García-Vigil JL, Giral-Barnés C, Hernández-Santillán D, Jasso-Gutiérrez L. Farmacovigilancia II. Las reacciones adversas y el Programa Internacional de Monitoreo de los Medicamentos. Rev Med IMSS. 2004;42(5):419-23.

  3. Bénichou C. Introduction. Adverse Drug Reactions. A practical guide to diagnosis and management. Paris: Wiley; 1999. p. xiii-xiv.

  4. Uppsala Monitoring Centre. Vigilancia de la seguridad de los medicamentos. Guía para la instalación y puesta en funcionamiento de un centro de farmacovigilancia [monografía en internet]. Suecia: UMC/OMS; 2001 [citado 13 Ag 2012]. Disponible en: http://who-umc.org/graphics/24751.pdf

  5. García-Rosas R, Haro-García L, Consideraciones generales sobre la farmacovigilancia. Rev Med IMSS. 2002;40(2):173-9.

  6. Agencia Española de Medicamentos y Productos Sanitarios. Transmisión electrónica de sospechas de reacciones adversas de medicamentos de uso humano. España, 2013 [citado 13 Sept 2013]. Disponible en: http://www.aemps.gob.es/oficinaVirtual/usoHum/farmacovig/transmielectronica. htm

  7. Organización Mundial de la Salud. La Farmacovigilancia: Garantía de seguridad en el uso de los medicamentos. Perspectivas políticas de la OMS sobre medicamentos. Ginebra: Organización Mundial de la Salud; 2004. p. 1-6.

  8. Secretaria de Salud. NORMA Oficial Mexicana NOM-220-SSA1-2002, Instalación y operación de la farmacovigilancia. México. 2012 [citado 13 Abr 2012]. Disponible en: http://www.salud.gob.mx/unidades/cdi/nom/220ssa102.html

  9. Organización Panamericana de la Salud. Buenas Prácticas de Farmacovigilancia para las Américas. Washington, DC: OPS; 2011 [citado 13 May 2013]. Disponible en: http://apps.who.int/medicinedocs/documents/s18625es/s18625es.pdf

  10. Morales DM, Ruiz AI, Morgado CC, González FX. Farmacovigilancia en Chile y el mundo. Rev Chil Infectol 2002 [citado 11 Abr 2012];19(1):S42-S45. Disponible en: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716- 10182002019100008&lng=es&nrm=iso&tlng=es

  11. Comisión Federal para la Protección contra Riesgos Sanitarios. 4to. Boletín Informativo Farmacovigilancia. México: COFEPRIS; 2010 [citado 13 May 2013]. Disponible en: http://www.cofepris.gob.mx/AZ/Paginas/Farmacovigilancia/Boletin- Informativo.aspx

  12. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385-96.

  13. López-González E, Herdeiro MT, Figueiras A. Determinants of Under-Reporting of Adverse Drug Reactions, A Systematic. Rev Drug Saf. 2009;32(1):19-31.

  14. Banerjee AK, Ingate S. Web-based patient-reported outcomes in drug safety and risk management: challenges and opportunities? Drug Saf. 2012 Jun 1;35(6):437-46.

  15. Rodríguez Duque R, Jiménez López G, Fernández Manchón E, González Delgado BE. Caracterización de las reacciones adversas medicamentosas en ancianos, Cuba. 2003-2005. Rev Cubana Farm. 2007;41(3):1-11.

  16. Hilmer SH. The dilemma of polypharmacy. Aust Prescr. 2008;31:2-3.

  17. Machado-Alba JE, Moncada-Escobar JC. Reacciones adversas medicamentosas en pacientes que consultaron a instituciones prestadoras de servicios en Pereira, Colombia. Rev Salud Pública. 2006;8(2):200-8.

  18. Munger MA. Polypharmacy and Combination Therapy in the Management of Hypertension in Elderly Patients with Co-Morbid Diabetes Meliitus. Drugs Aging. 2010;27(11):871-83.

  19. Girardin E, Vial T, Pham E, Evreux JC. Hypoglycemia induced by oral hypoglycemic agents. Records of the French Regional Pharmacovigilance Centers 1985-1990. Ann Med Interne (Paris). 1992;143(1):11-7.

  20. Wysowski DK, Armstrong G, Governale L. Rapid increase in the use of oral antidiabetic drugs in the United States, 1990-2001. Diabetes Care. 2003 Jun;26(6):1852-5.

  21. Berthet S, Olivier P, Montastruc JL, Lapeyre-Mestre M. Drug safety of rosiglitazone and pioglitazone in France: a study using the French pharmacovigilance database. BMC Clin Pharmacol. 2011 May 24;11:5.

  22. Caterson ID. Endocrine Diseases. In: Speight TM, Holford NHG, editors. Avery's Drug Treatment. 4th ed. New Zeland: Adis International; 1997. p. 156-68.

  23. Tracy JW, Webster LT. Drugs used in the chemotherapy of protozoal infections: Malaria. In: Hardman JE, Limbird RW, editors. Goodman & Gilman's. The Pharmacological Basis of Therapeutics, 10th ed. New York: McGraw-Hill; 2001. p. 1069-95.

  24. O'Brien AAJ, Bulpitt CJ. Hypertensive Diseases. In: Speight TM, Holford NHG, editors. Avery's Drug Treatment. 4th ed. New Zeland: Adis International; 1997. p. 75-87.

  25. Davis SN, Granner DK. Insulin, oral hypoglycemic agents, and the pharmacology of the andocrine pancreas. In: Hardman JE, Limbird RW, editors. Goodman & Gilman's. The Pharmacological Basis of Therapeutics. 10th ed. New York: McGraw-Hill; 2001. p. 1679-714.

  26. Campos-Sepúlveda AE, Martínez-Enríquez ME, Mendoza-Patiño N. Quinolonas Rev Fac Med UNAM. 2008;51:173-7.

  27. Piedad J, Rickards H, Besaq FM, Cavanna AE. Benefical and adverse psychotropic effects of antiepileptic drugs in patients with epilepsy: a summary of prevalence, undrlyng mechanisms and data limitations. CNS Drugs. 2012;26:319-35.

  28. Rodríguez-Carranza R. Vademécum Académico de Medicamentos. México, DF: Ed. McGraw-Hill Interamericana; 1999. p. 78-85.

  29. Heeley E, Riley J, Layton D, Wilton LV, Shakir SA. Prescription-event monitoring and reporting of adverse drug reactions. Lancet. 2001;358:1872-3.

  30. Tapia-Moreno VA. Detección, control y seguimiento de reacciones adversas a medicamentos (RAMS) en pacientes de la tercera edad diabéticos polimedicados del área de consulta externa del Hospital del IESS-RIOBAMBA [tesis]. Quito: Escuela Superior Politécnica De Chimborazo; 2011.

  31. Ortiz MI, Ponce-Monter HA, Fernández-Martínez E, Macías A, Izquierdo-Vega JA, Sánchez-Gutiérrez M, et al. Pharmacovigilance of psychoactive medications in a Mexican psychiatric hospital. Proc West Pharmacol Soc. 2010;53:44-5.

  32. Rawlins MD, Thompson JW. Pathogenesis of adverse drug reactions. In: Davies DM, ed. Textbook of adverse drug reactions. Oxford: Oxford University Press; 1977. p. 44.

  33. Rodríguez-Carranza R, Vidrio H, Campos-Sepúlveda E. La enseñanza de la farmacología en las escuelas de medicina, situación actual. Gac Méd Méx. 2008;6:463-72.

  34. Begaud B, Moride Y, Tubert-Bitter P. False-positives in spontaneous reporting: should we worry about them? Br J Clin Pharmacol. 1994;38:401-4.

  35. Lizcano L, Magaldi L. Farmacovigilancia del Midazolam en pacientes sometidos a estudios gastroscópicos. Arch Venezolanos Farmacol Terapéut 2001;20(2):139-42.

  36. Mino-León D, Reyes-Morales H, Galván-Plata ME, Ponce-Monter H, Palma-Aguirre JA, Amato D, et al. Drug treatment of hypertension: compliance and adverse reactions in a cohort of hypertensive patients in a primary care setting. Rev Invest Clin. 2007;59(1):8-14.




2020     |     www.medigraphic.com